EDNRA-Targeted Drug Discovery Services

Introduction

Endothelin receptor type A is also known as ETA. It is encoded by the EDNRA gene. The EDNRA gene encodes the receptor for endothelin-1, a peptide that plays a role in potent and long-lasting vasoconstriction. This receptor associates with guanine-nucleotide-binding (G) proteins, and this coupling activates a phosphatidylinositol-calcium second messenger system. Polymorphisms in this gene have been linked to migraine headache resistance. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2009]

Direction of Drugs Discovery

• EDNRA Antagonist
• EDNRA Modulator
• EDNRA Inhibitor
• EDNRA Agonist
• Developing New Clinical Effects on EDNRA from Existing Drugs

Drugs

• EDNRA Antagonist- Ambrisentan, LU302146, clazosentan, atrasentan, darusenta
• EDNRA Modulator- Bosentan, macitentan, PD-145065, BMS-193884, J-104132
• EDNRA Inhibitor- ET-1, BMS-182874, Ac-bhg-F-N-Y-Y-W, PD-163140, W-F-F-N--Y-Y-W
• EDNRA Agonist- Sarafotoxin S6b

What We Offer

Target Testing

CD BioSciences provides EDNRA testing services by WB, IHC, ICC, or IF assay. The results of EDNRA testing are used to evaluate the activities of candidates against EDNRA or targeted diseases. You can choose one or more testing ways to detect the level of EDNRA according to your experiment.

Hit Identification (show more)

The goal of early drug discovery is to find novel lead compounds that have the desired potency, selectivity, and ADMET properties for pre-clinical evaluation.
CD BioSciences offers hit identification services to make your finding of targeted compounds more successful and faster.
• High-Throughput Screening
• EDNRA-Targeted in Silico Virtual Screening
• Fragment-Based Screening
• High-Content Screening

Antibody Drugs Development Services (show more)

Antibody drugs exhibit many incomparable advantages, such as high specificity, affinity, and efficiency, which is an emerging direction on targeted drug development. CD BioSciences provides comprehensive services on EDNRA-targeted antibody drugs development with professional technology, extensive experience, and advanced equipment.
• Antibody Preparation Services
• Phage Display Services
• Antibody-Drug Conjugates
• Bispecific Antibody Services

Pharmacological Experiments (show more)

We will create a specific experimental plan according to your requirements, including but not limited to
• Pharmacokinetics / Pharmacodynamics
• Pharmacodynamics
• Pharmacokinetics
• Safety Pharmacology

Disease Models Screening (show more)

We will create specific disease models to accelerate your targeted drug discovery project, including but not limited to
• Cancers—Prostate cancer. (show more)
• Other Diseases—Pulmonary arterial hypertension, pulmonary hypertension, cardiovascular disease, diabetic nephropathy, cerebral vasospasm, hypertension.
CD BioSciences will establish the specific disease models according to your requirements to evaluate the inhibitory activity of your candidates targeted EDNRA. We have various cell lines and the species of our animal models cover rats, mice, rabbits, dogs, and non-human primates.

Inquire Us

References

1. Stelzer G.; et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analysis , Current Protocols in Bioinformatics(2016), 54:1.30.1 - 1.30.33.doi: 10.1002 / cpbi.5.
2. Wishart DS; et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue): D901-6.
3. Y. Zhou; et al. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Research. 50(D1): 1398-1407 (2022). PMID: 34718800.